PharmaTher unveils KetaVault portal

PharmaTher (PHRRF) Holdings announced the launch of KetaVault. This portal offers pharmaceutical and biotech companies, academic and clinical researchers, and government agencies to partner with PharmaTher for direct access to its comprehensive proprietary data on ketamine. KetaVault is strategically designed to streamline and accelerate clinical trials, regulatory submissions, and commercialization initiatives for ketamine-based therapies. The launch of KetaVault is strategically timed with the Company’s anticipated FDA approval for its ketamine product, which has an approval goal date of June 4, 2025. This dual milestone underscores PharmaTher’s commitment to leading innovation in the ketamine space. KetaVault is positioned to be a pivotal catalyst, empowering partners to leverage PharmaTher’s deep expertise and data to unlock new therapeutic avenues for ketamine in areas of high unmet medical need and for emergency use applications, potentially revolutionizing treatment paradigms.